| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong A.; Kim H.-J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:14:58Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; YEN-SHEN LU; Chuang E.Y.; Thiery J.P.; Huang C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-12-21T23:17:41Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2− advanced breast cancer
|
Fasching, Peter A.; Delea, Thomas E.; YEN-SHEN LU; De Boer, Richard; Hurvitz, Sara A.; Moynahan, Aaron; Chandiwana, David; Lanoue, Brad; Hu, Huilin; Thuerigen, Astrid; O’shaughnessy, Joyce |
| 臺大學術典藏 |
2021-11-21T23:19:52Z |
Genomic profiling of premenopausal HR+ and HER2– metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Vázquez, Rafael Villanueva; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu; YEN-SHEN LU |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong, Andrea; Kim, Hee Jeong |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo, Winnie; Yap, Yoon Sim; Park, Yeon Hee; Tamura, Kenji; Li, Huiping; Cheng, Rebecca |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai, Ming Shen; Feng, Yin Hsun; Chen, Shang Wen; Masuda, Norikazu; Yau, Thomas; Chen, Shou Tung; YEN-SHEN LU; Yap, Yoon Sim; Ang, Peter C.S.; Chu, Sung Chao; Kwong, Ava; Lee, Keun Seok; Ow, Samuel; Kim, Sung Bae; Lin, Johnson; Chung, Hyun Cheol; Ngan, Roger; Kok, Victor C.; Rau, Kun Ming; Sangai, Takafumi; Ng, Ting Ying; Tseng, Ling Ming; Bryce, Richard; Bebchuk, Judith; Chen, Mei Chieh; Hou, Ming Feng |
| 臺大學術典藏 |
2021-09-14T23:19:03Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
CHING-HUNG LIN; RUBY YUN-JU HUANG; TZU-PIN LU; KUAN-TING KUO; Lo, Ko Yun; Chen, Ching Hsuan; Chen, I. Chun; YEN-SHEN LU; Chuang, Eric Y.; Thiery, Jean Paul; CHIUN-SHENG HUANG; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
|
Chang, Dwan Ying; Ma, Wei Li; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-21T23:14:58Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata, Tomomi; Nakamura, Kenichi; Yonemori, Kan; Noguchi, Emi; Watanabe, Makiko; Sohn, Joohyuk; YEN-SHEN LU; Yap, Yoon Sim; Tamura, Kenji; Fujiwara, Yasuhiro |
| 臺大學術典藏 |
2021-03-10T02:36:33Z |
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
|
Harbeck N.;Franke F.;Villanueva-Vazquez R.;Yen-Shen Lu;Tripathy D.;Chow L.;Babu G.K.;Im Y.-H.;Chandiwana D.;Gaur A.;Lanoue B.;Rodriguez-Lorenc K.;Bardia A.; Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
|
Chen T.W.-W.;Jan I.-S.;Chang D.-Y.;Lin C.-H.;Chen I.-C.;Chen H.-M.;Cheng A.-L.;Yen-Shen Lu; Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Response to Sung, Rosenberg, and Yang
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)
|
Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; Lin C.-H.; YEN-SHEN LU; Wo A.M. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.;Chang S.-H.;Kuo W.-H.;Kuo C.-H.;Li S.-Y.;Wang M.-Y.;Chang D.-Y.;Yen-Shen Lu;Huang C.-S.;Cheng A.-L.;Lin C.-H.;Chen P.-C.; Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; YEN-SHEN LU; Huang C.-S.; Cheng A.-L.; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1
|
Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. |
| 臺大學術典藏 |
2021-03-03T10:26:44Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
Yen-Shen Lu; Lee, Keun Seok; Chao, Tsu Yi; Tseng, Ling Ming; Chitapanarux, Imjai; Chen, Shin Cheh; Liu, Chien Ting; Sohn, Joohyuk; Kim, Jee Hyun; Chang, Yuan Ching; Yang, Youngsen; Shotelersuk, Kanjana; Jung, Kyung Hae; Valenti, Roberta; Slader, Cassandra; Gao, Melissa; Park, Yeon Hee |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
